Oligonucleotides decoy to NF-kappaB: becoming a reality?
In the last two decades, frontiers in new drug development are represented by genetic code inhibitors. Nuclear factor-kappaB (NF-κB) is a transcription factor playing critical roles in many inflammatory/immune diseases. Decoy oligonucleotides (decoy ONs) epitomize an ideal pharmacological tool to selectively block NF-κB activation. Their use is currently being investigated in several chronic inflammatory-based diseases. However, decoy ONs' clinical use is strongly hampered by several issues. Chemical modifications and/or delivery systems have been investigated to overcome some of these limits. This review describes the successful preclinical and clinical applications of decoy ON against NF-κB in inflammatory-based diseases.